Stan Bukofzer has been named senior vice president, chief medical and scientific officer of Newark, CA-based Depomed (NASDAQ: DEPO). Bukofzer was most recently chief medical officer of Ocera Therapeutics, which was acquired by Mallinkrodt (NYSE: MNK) last year. He succeeds Santosh Vetticaden, who Depomed says decided not to relocate to the company’s new headquarters in Illinois. Vetticaden will remain with the company through the end of the month to help with the transition. Depomed develops and markets pain and neurology drugs.